{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
phenyl aminosalicylate
to a specific field?
Status:
Investigational
Source:
NCT03394677: Phase 2 Interventional Completed Atopic Dermatitis
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
E-6005 is a novel PDE4 inhibitor developed as a topical agent for atopic dermatitis (AD). It potently and selectively inhibited human PDE4 activity and suppressed the production of various cytokines from human lymphocytes and monocytes. In mice models, the topical application of E6005 produced an immediate antipruritic effect as well as an anti-inflammatory effect with reduced expression of cytokines/adhesion molecules. E-6005 increases the cutaneous concentration of cAMP to relieve dermatitis-associated itching. E-6005 may be a promising novel therapeutic agent with antipruritic activity for the treatment of AD. E-6005 is currently in phase 2 development for patients with mild-to-moderate atopic dermatitis.
Status:
Investigational
Source:
NCT01782664: Phase 2 Interventional Completed Psoriasis
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Solcitinib (also known as GSK2586184 or GLPG0778) is a selective Janus kinase 1 (JAK1) inhibitor, for the treatment of psoriasis, lupus, and ulcerative colitis. Galapagos NV's collaboration with GlaxoSmithKline has hit a roadblock. It was reported that its Big Pharma partner had hit the brakes on a Phase II study of GSK2586184 for lupus after a first look at the data failed to demonstrate a positive effect. And an exploratory Phase I/II of the same drug for ulcerative colitis was put on hold as investigators review the program.
Status:
Investigational
Source:
NCT03681093: Phase 3 Interventional Completed Nasal Polyps
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Fevipiprant is a selective reversible antagonist of the prostaglandin D2 receptor (also known as CRTH2). It is currently in development for the treatment of allergic diseases.
Status:
Investigational
Source:
NCT03320486: Phase 3 Interventional Completed Tinea Pedis
(2017)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Dapaconazole is an imidazolic compound developed by Biolab Sanus Farmaceutica for the treatment of fungal infections. Dapaconazole was investigated in several clinical trials. In patients with Pityriasis versicolor infections, dapaconazole demonstrated a good safety profile and was non-inferior to ketoconazole when topically applied as a 2% cream at a dose of 20 mg/day for 28 consecutive days. The drug is being investigated in phase 3 clinical trial for the treatment of Tinea Pedis.
Status:
Investigational
Source:
NCT02753764: Phase 2 Interventional Completed Corticosteroid Resistant (CR) Asthmatics
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:mirivadelgat [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01970215: Phase 2 Interventional Completed Dyslipidemia
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04129944: Phase 2 Interventional Completed Osteoarthritis, Knee
(2019)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Nutlins are cis-imidazoline analogs which inhibit the interaction between mdm2 and tumour suppressor p53. Inhibiting the interaction between mdm2 and p53 stabilizes p53, and is thought to selectively induce a growth-inhibiting state called senescence in cancer cells. These compounds are therefore thought to work best on tumors that contain normal or "wild-type" p53. Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis.
Status:
Investigational
Source:
NCT02190279: Early Phase 1 Interventional Completed Prostatic Neoplasms
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
DCFBC F-18 is a radioconjugate containing a low molecular weight tracer, DCFBC, specific for prostate-specific membrane antigen (PSMA) and labeled with the positron-emitting isotope fluorine F 18 with potential prostate tumor imaging upon positron emission tomography (PET). Upon administration, the DCFBC moiety of fluorine F 18 DCFBC specifically targets and binds to the tumor-associated antigen PSMA, thereby allowing the visualization of tumor cells expressing PSMA upon PET. F 18 DCFBC is investigated in phase 2 clinical trials in patients with prostate cancer.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Phenovalin is the laxative agent.
